McKinsey and the Opioid Crisis: The Consultants’ Role in a National Tragedy
This month the global consulting firm McKinsey & Company agreed to pay $650 million to settle a federal investigation into its collaboration with Purdue Pharma, the maker of OxyContin, a highly addictive opioid medication.
This settlement is the latest chapter in a scandal that has rocked both the pharmaceutical and consulting industries, linking McKinsey to a public health crisis that has cost thousands of lives in recent years.
McKinsey, known for its influence on large corporations and governments, agreed to pay the sum mentioned to avoid criminal charges related to its work with Purdue Pharma, which aggressively promoted the sales of OxyContin. The settlement also mandates that McKinsey refrain from engaging in the promotion of controlled substances for the next five years.
This decision underscores a clear warning to the consulting industry: complicity in illegal or immoral activities will not go unpunished.
The payment from McKinsey is part of a broader federal effort to hold accountable those companies that, either actively or passively, contributed to the addiction and overdose crisis in the United States.
In recent years, more than 80,000 deaths per year have been attributed to opioid abuse, and in its early years, OxyContin played a crucial role in this tragedy.
McKinsey’s Strategy: Aggressive Marketing of OxyContin
Court documents reveal chilling details about how McKinsey worked to maximize Purdue Pharma’s profits.
The firm identified key doctors and prescribers who could increase the number of OxyContin prescriptions, even when they were aware of the risks associated with the drug. According to prosecutors, McKinsey not only advised on sales promotion but also helped identify markets where OxyContin could be distributed without restrictions, regardless of the public health consequences.
$93 Million for Advising on OxyContin
Over 15 years, McKinsey received more than $93 million from Purdue Pharma to advise on optimizing OxyContin sales.
This contract has been one of the most controversial points in the relationship between the two entities, as it has been shown that McKinsey not only provided marketing advice but also helped Purdue find ways to bypass federal regulations that could have limited the distribution of their products.
Throughout the years, Purdue and McKinsey worked together to identify opioid prescribers and encourage the issuing of prescriptions for OxyContin, many of which were outside the parameters of legitimate medical use.
Federal prosecutors describe these practices as a «deliberate effort» to expand the sales of the drug without regard to the consequences of this expansion. According to the prosecutors, McKinsey’s actions directly contributed to an increase in prescriptions that were not only unnecessary but also dangerous to public health.
Influence on Health Policy
What makes this case even more disturbing is the role McKinsey played in shaping federal opioid policies.
The firm not only advised on how to increase sales, but it also influenced the creation of federal guidelines that favored Purdue Pharma and other opioid manufacturers.
According to court filings, McKinsey helped lobby for more lenient opioid prescribing guidelines, allowing high-dose OxyContin to be treated similarly to low-dose opioids.
This type of corporate influence on public policy highlights a larger issue: the power of large consultancies and corporations over public health and regulations. Efforts to maximize profits at the expense of public safety have been a constant in the pharmaceutical industry, and this case shows how consultants, just like companies, can be complicit in pushing decisions that negatively affect society.
The Devastation of the Opioid Crisis
The opioid crisis in the United States has been devastating, with millions of lives affected by addiction and thousands of deaths each year.
Although the abuse of illicit fentanyl has now replaced prescription opioid abuse as the leading cause of death, painkillers like OxyContin are still responsible for a significant number of addictions and overdoses.
The actions of companies like Purdue and their partner McKinsey have exacerbated this crisis, contributing to the suffering of thousands of families across the country. The resolution of the McKinsey case not only involves a financial payout but also an acknowledgment of their responsibility in this disaster.
Although the settlement will allow McKinsey to avoid criminal charges, we must not forget that the damage caused by these companies far exceeds any amount of money they can pay in compensation.
About The Author
